Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera''s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. The test is available for clinical and research use, and has been designated by the FDA as a Breakthrough Device. Look deeper at natera.com/oncology
Products